GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » E10

Gyre Therapeutics (Gyre Therapeutics) E10 : $0.00 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Gyre Therapeutics's adjusted earnings per share data for the fiscal year that ended in Dec. 2023 was $-1.410. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $0.00 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-05-28), Gyre Therapeutics's current stock price is $ 10.1855. Gyre Therapeutics's E10 for the fiscal year that ended in Dec. 2023 was $0.00. Gyre Therapeutics's Shiller PE Ratio of today is .


Gyre Therapeutics E10 Historical Data

The historical data trend for Gyre Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics E10 Chart

Gyre Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
E10
- - -

Gyre Therapeutics Semi-Annual Data
Dec21 Dec22 Dec23
E10 - - -

Competitive Comparison of Gyre Therapeutics's E10

For the Biotechnology subindustry, Gyre Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gyre Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Gyre Therapeutics's Shiller PE Ratio falls into.



Gyre Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Gyre Therapeutics's adjusted earnings per share data for the fiscal year that ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.41/129.4194*129.4194
=-1.410

Current CPI (Dec. 2023) = 129.4194.

Gyre Therapeutics does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate it.


Gyre Therapeutics  (NAS:GYRE) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Gyre Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Gyre Therapeutics (Gyre Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
Address
12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Gyre Therapeutics (Gyre Therapeutics) Headlines